Steven David Freedman, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 48 | 2024 | 1274 | 6.500 |
Why?
|
| Pancreatitis | 42 | 2024 | 1096 | 5.630 |
Why?
|
| Pancreatitis, Chronic | 37 | 2024 | 281 | 4.300 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 27 | 2022 | 446 | 3.140 |
Why?
|
| Exocrine Pancreatic Insufficiency | 7 | 2024 | 84 | 2.320 |
Why?
|
| Gastrointestinal Diseases | 10 | 2024 | 1184 | 2.230 |
Why?
|
| Docosahexaenoic Acids | 18 | 2019 | 905 | 1.810 |
Why?
|
| Enteral Nutrition | 11 | 2023 | 785 | 1.700 |
Why?
|
| Lipase | 6 | 2023 | 324 | 1.520 |
Why?
|
| Hypertriglyceridemia | 4 | 2023 | 293 | 1.460 |
Why?
|
| Pancreas | 15 | 2023 | 1676 | 1.250 |
Why?
|
| Fatty Acids | 14 | 2021 | 1804 | 1.150 |
Why?
|
| Arachidonic Acid | 6 | 2019 | 427 | 0.930 |
Why?
|
| Acute Disease | 30 | 2024 | 7226 | 0.890 |
Why?
|
| Fatty Acids, Omega-3 | 4 | 2023 | 1373 | 0.850 |
Why?
|
| Bile Ducts | 4 | 2012 | 282 | 0.830 |
Why?
|
| Gastroenterology | 2 | 2020 | 571 | 0.820 |
Why?
|
| Abdominal Pain | 11 | 2023 | 1064 | 0.780 |
Why?
|
| Fatty Acids, Unsaturated | 3 | 2019 | 540 | 0.760 |
Why?
|
| Infant, Premature | 7 | 2022 | 2093 | 0.750 |
Why?
|
| Milk, Human | 5 | 2022 | 483 | 0.730 |
Why?
|
| Pancreatic Function Tests | 7 | 2017 | 69 | 0.710 |
Why?
|
| Inservice Training | 2 | 2017 | 375 | 0.620 |
Why?
|
| Triglycerides | 6 | 2023 | 2450 | 0.610 |
Why?
|
| Pancreatectomy | 3 | 2017 | 808 | 0.600 |
Why?
|
| Fats | 1 | 2018 | 99 | 0.590 |
Why?
|
| Liver Diseases | 2 | 2019 | 1295 | 0.580 |
Why?
|
| Pancreatic Diseases | 1 | 2019 | 343 | 0.580 |
Why?
|
| Infant Nutritional Physiological Phenomena | 3 | 2022 | 351 | 0.570 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2017 | 79 | 0.560 |
Why?
|
| Food, Formulated | 1 | 2017 | 101 | 0.560 |
Why?
|
| Linoleic Acid | 5 | 2010 | 158 | 0.550 |
Why?
|
| Gastrointestinal Tract | 3 | 2018 | 830 | 0.540 |
Why?
|
| Lipids | 5 | 2020 | 3326 | 0.500 |
Why?
|
| Intestines | 3 | 2020 | 1906 | 0.450 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2007 | 177 | 0.440 |
Why?
|
| Ileum | 5 | 2020 | 556 | 0.430 |
Why?
|
| Nose | 1 | 2016 | 519 | 0.420 |
Why?
|
| Pancreatic Neoplasms | 6 | 2023 | 5348 | 0.410 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 8 | 2022 | 505 | 0.400 |
Why?
|
| Hyperoxia | 1 | 2014 | 250 | 0.400 |
Why?
|
| Secretin | 3 | 2017 | 57 | 0.400 |
Why?
|
| Humans | 149 | 2024 | 757650 | 0.390 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2007 | 855 | 0.380 |
Why?
|
| Lipoxins | 1 | 2014 | 418 | 0.380 |
Why?
|
| Mice, Inbred CFTR | 7 | 2012 | 18 | 0.370 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 2 | 2007 | 61 | 0.360 |
Why?
|
| Eicosanoids | 2 | 2010 | 278 | 0.360 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2020 | 1723 | 0.350 |
Why?
|
| Colitis | 2 | 2012 | 1231 | 0.350 |
Why?
|
| Lipopolysaccharides | 4 | 2021 | 2204 | 0.340 |
Why?
|
| Erythrocytes | 2 | 2018 | 2413 | 0.330 |
Why?
|
| Lung Injury | 1 | 2014 | 424 | 0.330 |
Why?
|
| Aminophenols | 4 | 2022 | 86 | 0.330 |
Why?
|
| Intestinal Absorption | 2 | 2023 | 400 | 0.330 |
Why?
|
| Medicine | 2 | 2020 | 940 | 0.310 |
Why?
|
| Enterocolitis, Necrotizing | 3 | 2020 | 326 | 0.310 |
Why?
|
| Gallstones | 2 | 2022 | 283 | 0.300 |
Why?
|
| Respiratory Mucosa | 2 | 2010 | 441 | 0.290 |
Why?
|
| Chlorides | 5 | 2022 | 663 | 0.290 |
Why?
|
| Office Visits | 1 | 2011 | 594 | 0.290 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2009 | 264 | 0.290 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2022 | 623 | 0.290 |
Why?
|
| Dietary Fats | 4 | 2020 | 1991 | 0.290 |
Why?
|
| Interleukin-8 | 3 | 2015 | 696 | 0.290 |
Why?
|
| Transcranial Magnetic Stimulation | 6 | 2010 | 1469 | 0.280 |
Why?
|
| Breast Feeding | 3 | 2018 | 1355 | 0.280 |
Why?
|
| Alcoholism | 3 | 2022 | 1964 | 0.280 |
Why?
|
| Curriculum | 1 | 2020 | 3715 | 0.280 |
Why?
|
| Macrophages, Peritoneal | 1 | 2007 | 237 | 0.270 |
Why?
|
| Short Bowel Syndrome | 2 | 2023 | 353 | 0.270 |
Why?
|
| Disease Management | 3 | 2017 | 2495 | 0.270 |
Why?
|
| Patient Participation | 2 | 2012 | 1435 | 0.270 |
Why?
|
| Recurrence | 15 | 2022 | 8426 | 0.250 |
Why?
|
| Chloride Channels | 2 | 2004 | 221 | 0.250 |
Why?
|
| Trans-Activators | 3 | 2004 | 2859 | 0.250 |
Why?
|
| Mutation | 18 | 2022 | 29928 | 0.250 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2006 | 226 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 6 | 2019 | 7366 | 0.240 |
Why?
|
| Quality Improvement | 3 | 2019 | 3793 | 0.240 |
Why?
|
| Benchmarking | 1 | 2011 | 1042 | 0.240 |
Why?
|
| PPAR alpha | 1 | 2006 | 175 | 0.240 |
Why?
|
| Liver Cirrhosis | 2 | 2012 | 1931 | 0.230 |
Why?
|
| Insulin | 2 | 2022 | 6578 | 0.230 |
Why?
|
| Colon | 3 | 2009 | 1788 | 0.230 |
Why?
|
| Adult | 45 | 2024 | 219747 | 0.230 |
Why?
|
| Autoimmune Diseases | 3 | 2018 | 2243 | 0.230 |
Why?
|
| Quinolones | 3 | 2022 | 377 | 0.230 |
Why?
|
| Male | 68 | 2024 | 358227 | 0.230 |
Why?
|
| Pancrelipase | 1 | 2023 | 7 | 0.220 |
Why?
|
| Disease Models, Animal | 12 | 2020 | 18123 | 0.220 |
Why?
|
| Delphi Technique | 3 | 2022 | 829 | 0.220 |
Why?
|
| Phospholipids | 2 | 2007 | 784 | 0.220 |
Why?
|
| Sweat | 5 | 2010 | 56 | 0.220 |
Why?
|
| Dietary Supplements | 3 | 2019 | 3388 | 0.220 |
Why?
|
| Pancreatitis, Alcoholic | 2 | 2022 | 28 | 0.220 |
Why?
|
| Swine | 6 | 2023 | 5892 | 0.220 |
Why?
|
| Child | 28 | 2024 | 79787 | 0.220 |
Why?
|
| Infant, Premature, Diseases | 2 | 2022 | 708 | 0.210 |
Why?
|
| Animals | 34 | 2023 | 167777 | 0.210 |
Why?
|
| Retinopathy of Prematurity | 2 | 2022 | 432 | 0.210 |
Why?
|
| Dextran Sulfate | 3 | 2012 | 256 | 0.210 |
Why?
|
| Female | 67 | 2024 | 389985 | 0.210 |
Why?
|
| Lung | 6 | 2022 | 9979 | 0.200 |
Why?
|
| Animals, Newborn | 6 | 2021 | 2673 | 0.200 |
Why?
|
| Lipolysis | 1 | 2023 | 209 | 0.200 |
Why?
|
| Mice, Knockout | 9 | 2018 | 14354 | 0.200 |
Why?
|
| Choledocholithiasis | 1 | 2022 | 49 | 0.200 |
Why?
|
| Quality of Life | 9 | 2024 | 13265 | 0.200 |
Why?
|
| Prospective Studies | 16 | 2024 | 54108 | 0.200 |
Why?
|
| Nasal Mucosa | 5 | 2010 | 412 | 0.190 |
Why?
|
| Genetic Testing | 3 | 2010 | 3529 | 0.190 |
Why?
|
| Needs Assessment | 2 | 2017 | 1139 | 0.190 |
Why?
|
| Decision Making | 2 | 2012 | 3909 | 0.190 |
Why?
|
| Food, Fortified | 1 | 2022 | 189 | 0.190 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 2743 | 0.190 |
Why?
|
| Analgesics, Opioid | 7 | 2022 | 3762 | 0.190 |
Why?
|
| Electric Stimulation Therapy | 4 | 2009 | 613 | 0.190 |
Why?
|
| Infant, Newborn | 11 | 2022 | 26173 | 0.190 |
Why?
|
| Lung Diseases | 1 | 2011 | 1908 | 0.180 |
Why?
|
| Postprandial Period | 1 | 2003 | 314 | 0.180 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2015 | 508 | 0.180 |
Why?
|
| Oxylipins | 1 | 2021 | 52 | 0.180 |
Why?
|
| Pain | 8 | 2022 | 5063 | 0.180 |
Why?
|
| Consensus | 2 | 2023 | 3098 | 0.180 |
Why?
|
| Hydrolysis | 2 | 2017 | 664 | 0.180 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 421 | 0.180 |
Why?
|
| Chymotrypsin | 2 | 2017 | 138 | 0.180 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2023 | 355 | 0.180 |
Why?
|
| Fatty Acid Transport Proteins | 1 | 2019 | 31 | 0.170 |
Why?
|
| Infant | 11 | 2022 | 36043 | 0.170 |
Why?
|
| Adolescent | 22 | 2024 | 87832 | 0.170 |
Why?
|
| Hyperlipoproteinemia Type I | 1 | 2019 | 11 | 0.170 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2019 | 56 | 0.170 |
Why?
|
| DNA-Binding Proteins | 3 | 2007 | 9574 | 0.170 |
Why?
|
| Injections, Subcutaneous | 2 | 2019 | 678 | 0.170 |
Why?
|
| Fatty Acids, Essential | 1 | 2020 | 97 | 0.170 |
Why?
|
| Infant Formula | 2 | 2016 | 193 | 0.170 |
Why?
|
| Trypsin | 2 | 2017 | 496 | 0.170 |
Why?
|
| Child, Preschool | 14 | 2024 | 42044 | 0.160 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2023 | 409 | 0.160 |
Why?
|
| Liver | 3 | 2012 | 7503 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 5815 | 0.160 |
Why?
|
| Arachidonic Acids | 1 | 2019 | 294 | 0.160 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 419 | 0.160 |
Why?
|
| Restless Legs Syndrome | 1 | 2022 | 233 | 0.160 |
Why?
|
| Mice | 20 | 2020 | 81107 | 0.160 |
Why?
|
| Erythrocyte Count | 1 | 2018 | 156 | 0.150 |
Why?
|
| Deep Brain Stimulation | 4 | 2007 | 825 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2011 | 3239 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 1702 | 0.150 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2018 | 65 | 0.150 |
Why?
|
| Carrier Proteins | 4 | 2016 | 4937 | 0.150 |
Why?
|
| RNA, Messenger | 5 | 2019 | 12761 | 0.150 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2022 | 316 | 0.150 |
Why?
|
| Apolipoprotein C-III | 1 | 2019 | 208 | 0.150 |
Why?
|
| Infusions, Subcutaneous | 1 | 2017 | 43 | 0.150 |
Why?
|
| Intestinal Mucosa | 4 | 2020 | 3023 | 0.150 |
Why?
|
| Peptide YY | 1 | 2018 | 136 | 0.150 |
Why?
|
| Bicarbonates | 2 | 2017 | 292 | 0.150 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2020 | 314 | 0.150 |
Why?
|
| Chronic Disease | 12 | 2020 | 9265 | 0.150 |
Why?
|
| Retrospective Studies | 19 | 2024 | 79982 | 0.150 |
Why?
|
| Communication | 1 | 2011 | 3842 | 0.140 |
Why?
|
| Jaundice, Obstructive | 1 | 2017 | 20 | 0.140 |
Why?
|
| Pancreatic Juice | 1 | 2017 | 60 | 0.140 |
Why?
|
| Heterozygote | 4 | 2004 | 2797 | 0.140 |
Why?
|
| Transcription Factors | 4 | 2004 | 12092 | 0.140 |
Why?
|
| Critical Pathways | 2 | 2018 | 473 | 0.140 |
Why?
|
| Hospitalization | 8 | 2024 | 10633 | 0.140 |
Why?
|
| Fish Oils | 1 | 2021 | 481 | 0.140 |
Why?
|
| Endosonography | 2 | 2020 | 607 | 0.140 |
Why?
|
| Polysaccharides | 2 | 2020 | 1007 | 0.140 |
Why?
|
| Disease Progression | 6 | 2022 | 13464 | 0.130 |
Why?
|
| Oligonucleotides | 1 | 2019 | 582 | 0.130 |
Why?
|
| Cross-Over Studies | 3 | 2017 | 2048 | 0.130 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2017 | 560 | 0.130 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 2141 | 0.130 |
Why?
|
| Registries | 4 | 2023 | 8164 | 0.130 |
Why?
|
| Middle Aged | 29 | 2024 | 219219 | 0.130 |
Why?
|
| Isoproterenol | 2 | 2007 | 394 | 0.130 |
Why?
|
| Length of Stay | 7 | 2023 | 6384 | 0.130 |
Why?
|
| Mice, Transgenic | 6 | 2019 | 9519 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2007 | 3047 | 0.120 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2022 | 866 | 0.120 |
Why?
|
| Malabsorption Syndromes | 1 | 2016 | 135 | 0.120 |
Why?
|
| Mucin 5AC | 1 | 2015 | 97 | 0.120 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 2 | 2016 | 30 | 0.120 |
Why?
|
| Monocytes | 1 | 2004 | 2570 | 0.120 |
Why?
|
| Eating | 1 | 2022 | 1537 | 0.120 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 996 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2012 | 4760 | 0.120 |
Why?
|
| Ion Transport | 2 | 2007 | 318 | 0.120 |
Why?
|
| Brain | 6 | 2019 | 26950 | 0.120 |
Why?
|
| Young Adult | 12 | 2024 | 58764 | 0.120 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 1651 | 0.120 |
Why?
|
| Research | 1 | 2023 | 1975 | 0.120 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2003 | 2753 | 0.120 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2010 | 748 | 0.120 |
Why?
|
| Organoids | 1 | 2020 | 729 | 0.120 |
Why?
|
| Intestine, Small | 1 | 2020 | 1205 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2018 | 493 | 0.120 |
Why?
|
| Neuronal Plasticity | 2 | 2016 | 1429 | 0.120 |
Why?
|
| Cadherins | 1 | 2019 | 898 | 0.120 |
Why?
|
| Biomedical Research | 3 | 2021 | 3416 | 0.110 |
Why?
|
| Energy Intake | 2 | 2023 | 2127 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 3171 | 0.110 |
Why?
|
| Pancreaticojejunostomy | 1 | 2013 | 26 | 0.110 |
Why?
|
| Drainage | 2 | 2020 | 1156 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 9 | 2020 | 22008 | 0.110 |
Why?
|
| Metabolome | 1 | 2020 | 982 | 0.110 |
Why?
|
| Genotype | 7 | 2019 | 12951 | 0.110 |
Why?
|
| Evoked Potentials, Motor | 1 | 2016 | 461 | 0.110 |
Why?
|
| Severity of Illness Index | 9 | 2024 | 15782 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2023 | 1599 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2019 | 4567 | 0.110 |
Why?
|
| Membrane Potentials | 3 | 2010 | 1094 | 0.100 |
Why?
|
| Double-Blind Method | 6 | 2019 | 12260 | 0.100 |
Why?
|
| Glucocorticoids | 2 | 2017 | 2145 | 0.100 |
Why?
|
| Pancreatic Elastase | 2 | 2022 | 128 | 0.100 |
Why?
|
| Adipocytes | 1 | 2019 | 1178 | 0.100 |
Why?
|
| Amylases | 1 | 2012 | 169 | 0.100 |
Why?
|
| Time Factors | 11 | 2018 | 39815 | 0.100 |
Why?
|
| Body Composition | 1 | 2022 | 2416 | 0.100 |
Why?
|
| Health Care Costs | 2 | 2016 | 3234 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2003 | 2976 | 0.100 |
Why?
|
| Risk Factors | 16 | 2024 | 73716 | 0.100 |
Why?
|
| Patient Care | 1 | 2017 | 621 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 5786 | 0.100 |
Why?
|
| Benzodioxoles | 2 | 2022 | 74 | 0.100 |
Why?
|
| Early Diagnosis | 3 | 2015 | 1177 | 0.100 |
Why?
|
| Pilot Projects | 5 | 2023 | 8551 | 0.100 |
Why?
|
| Neonatal Screening | 2 | 2009 | 594 | 0.100 |
Why?
|
| Case-Control Studies | 7 | 2022 | 22024 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2018 | 1474 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 1173 | 0.100 |
Why?
|
| Pulmonary Alveoli | 1 | 2014 | 651 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2004 | 611 | 0.100 |
Why?
|
| Cell Count | 2 | 2008 | 1835 | 0.090 |
Why?
|
| Pediatrics | 2 | 2017 | 3586 | 0.090 |
Why?
|
| Protein Conformation | 3 | 2003 | 3967 | 0.090 |
Why?
|
| Aged | 19 | 2024 | 167889 | 0.090 |
Why?
|
| Cohort Studies | 10 | 2022 | 41198 | 0.090 |
Why?
|
| Peptides | 1 | 2003 | 4340 | 0.090 |
Why?
|
| Fractures, Bone | 1 | 2023 | 2040 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 2 | 2010 | 1477 | 0.090 |
Why?
|
| Pneumonia | 1 | 2002 | 2127 | 0.090 |
Why?
|
| Morbidity | 1 | 2015 | 1748 | 0.090 |
Why?
|
| Treatment Outcome | 13 | 2022 | 64242 | 0.090 |
Why?
|
| Trypsinogen | 1 | 2010 | 84 | 0.090 |
Why?
|
| Emulsions | 2 | 2021 | 152 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2022 | 3299 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2016 | 949 | 0.090 |
Why?
|
| Pain, Postoperative | 2 | 2022 | 1715 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2023 | 3428 | 0.080 |
Why?
|
| Radiology | 1 | 2023 | 2101 | 0.080 |
Why?
|
| Emergency Service, Hospital | 5 | 2023 | 7801 | 0.080 |
Why?
|
| Feces | 1 | 2016 | 1457 | 0.080 |
Why?
|
| Access to Information | 1 | 2012 | 316 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 1791 | 0.080 |
Why?
|
| Review Literature as Topic | 2 | 2023 | 346 | 0.080 |
Why?
|
| Models, Molecular | 3 | 2003 | 5411 | 0.080 |
Why?
|
| Administration, Oral | 4 | 2006 | 3995 | 0.080 |
Why?
|
| Alcohol Drinking | 2 | 2019 | 4019 | 0.080 |
Why?
|
| Constipation | 2 | 2024 | 561 | 0.080 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2009 | 114 | 0.080 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2008 | 37 | 0.080 |
Why?
|
| Respiratory Therapy | 1 | 2009 | 125 | 0.080 |
Why?
|
| Patient Readmission | 4 | 2024 | 3241 | 0.080 |
Why?
|
| Prevalence | 5 | 2019 | 15641 | 0.080 |
Why?
|
| Transcription, Genetic | 3 | 2019 | 7590 | 0.080 |
Why?
|
| Bile Acids and Salts | 2 | 2023 | 383 | 0.080 |
Why?
|
| Hematocrit | 1 | 2009 | 625 | 0.070 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2011 | 399 | 0.070 |
Why?
|
| Age Factors | 4 | 2019 | 18328 | 0.070 |
Why?
|
| Bronchiectasis | 1 | 2009 | 139 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2012 | 1082 | 0.070 |
Why?
|
| Nutritional Support | 1 | 2009 | 172 | 0.070 |
Why?
|
| Somatosensory Cortex | 2 | 2010 | 511 | 0.070 |
Why?
|
| United States | 8 | 2023 | 71907 | 0.070 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2007 | 63 | 0.070 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2009 | 170 | 0.070 |
Why?
|
| Diagnosis, Differential | 5 | 2017 | 12950 | 0.070 |
Why?
|
| Cholecystectomy | 2 | 2020 | 406 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2003 | 13447 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2022 | 12870 | 0.070 |
Why?
|
| Overweight | 1 | 2018 | 2408 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2010 | 3757 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 12076 | 0.070 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2007 | 100 | 0.070 |
Why?
|
| Pain Measurement | 5 | 2020 | 3523 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2009 | 1828 | 0.070 |
Why?
|
| Prognosis | 7 | 2023 | 29493 | 0.070 |
Why?
|
| Random Allocation | 3 | 2019 | 2387 | 0.070 |
Why?
|
| Inflammation | 3 | 2023 | 10718 | 0.070 |
Why?
|
| Peripheral Nervous System | 1 | 2007 | 151 | 0.070 |
Why?
|
| Visceral Afferents | 1 | 2005 | 9 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 2003 | 17617 | 0.070 |
Why?
|
| Radiography, Abdominal | 1 | 2009 | 532 | 0.070 |
Why?
|
| Pyridines | 2 | 2022 | 2864 | 0.070 |